pyrazines has been researched along with Cryoglobulinemia in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Besada, E; Koldingsnes, W; Nossent, JC; Vik, A | 1 |
| Claxton, D; Fink, L; Talamo, G; Tricot, G; Zangari, M | 1 |
| Gunsilius, E; Mitterer, M; Spizzo, G | 1 |
| Bagot, M; Bezier, M; Cordoliani, F; Delyon, J; Malphettes, M; Rybojad, M; Szalat, R | 1 |
1 review(s) available for pyrazines and Cryoglobulinemia
| Article | Year |
|---|---|
Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Boronic Acids; Bortezomib; Cryoglobulinemia; Female; Humans; Pyrazines; Rituximab; Treatment Failure; Treatment Outcome; Vasculitis | 2013 |
3 other study(ies) available for pyrazines and Cryoglobulinemia
| Article | Year |
|---|---|
Response to bortezomib in refractory type I cryoglobulinemia.
Topics: Boronic Acids; Bortezomib; Cryoglobulinemia; Humans; Male; Middle Aged; Protease Inhibitors; Pyrazines; Vasculitis | 2008 |
Bortezomib for the treatment of refractory Type-1 cryoglobulinaemia.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Cryoglobulinemia; Humans; Male; Protease Inhibitors; Pyrazines; Skin Diseases, Vascular; Vasculitis | 2010 |
[Cutaneous manifestations revealing cryofibrinogenaemia associated with monoclonal gammopathy].
Topics: Acute Kidney Injury; Adult; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Biopsy; Boronic Acids; Bortezomib; Cryoglobulinemia; Cryoglobulins; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Female; Fibrinogens, Abnormal; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Kidney; Leg Ulcer; Microscopy, Fluorescence; Necrosis; Paraproteinemias; Plasmapheresis; Prednisone; Pyrazines; Skin | 2013 |